華安醫學股份有限公司
華安醫學股份有限公司（Ace Biotek）為一家新藥開發與科學儀器供應商。公司核心技術為「ENERGI 藥物研發平台」，透過增加細胞內 ATP 能量，促進受損細胞修復。核心新藥管線包含：治療糖尿病足潰瘍（F703）、防止落髮（F701）及巴金森氏症控制。除了醫藥開發，公司亦銷售高階生命科學實驗室用設備與化學試劑，提供生物技術諮詢與分析服務。公司成立於 2012 年，總部位於台灣台北市。
今日下跌 1.35%，股價跌破短期均線。該股 RSI(6) 為 42.0，處於中性區間，短線無明顯超買超賣訊號。股價站上60日均線，跌破5日、20日、120日均線。短中期均線呈多頭排列，趨勢偏多。KD 指標中性（K=26.1）；MACD 柱狀體為負值，空方動能持續。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 09-24 | -17 | 0 | 0 | -17 |
| 09-23 | -33 | 0 | -1 | -34 |
| 09-22 | +90 | 0 | +1 | +91 |
| 09-21 | +38 | 0 | +1 | +39 |
| 09-18 | -13 | 0 | +1 | -12 |
| 09-17 | -8 | 0 | 0 | -8 |
| 09-16 | -2 | 0 | 0 | -2 |
| 09-15 | +59 | 0 | 0 | +59 |
| 09-14 | -26 | 0 | 0 | -26 |
| 09-11 | -29 | 0 | 0 | -29 |
| 09-10 | -222 | 0 | 0 | -222 |
| 09-09 | -439 | 0 | +1 | -438 |
| 09-08 | +103 | 0 | +2 | +105 |
| 09-07 | +99 | 0 | 0 | +99 |
| 09-04 | -13 | 0 | 0 | -13 |
| 09-03 | +1 | 0 | 0 | +1 |
| 09-02 | +1 | 0 | 0 | +1 |
| 09-01 | +26 | 0 | +1 | +27 |
| 08-31 | -4 | 0 | 0 | -4 |
| 08-28 | -6 | 0 | 0 | -6 |
| 08-27 | +15 | 0 | 0 | +15 |
| 08-26 | +44 | 0 | +1 | +45 |
| 08-25 | 0 | 0 | 0 | 0 |
| 08-24 | -18 | 0 | 0 | -18 |
| 08-21 | +9 | 0 | 0 | +9 |
| 08-20 | +29 | 0 | 0 | +29 |
| 08-19 | +29 | 0 | 0 | +29 |
| 08-18 | -11 | 0 | 0 | -11 |
| 08-17 | -7 | 0 | 0 | -7 |
| 08-14 | -15 | 0 | 0 | -15 |
| 08-13 | +46 | 0 | 0 | +46 |
| 08-12 | +38 | 0 | 0 | +38 |
| 08-11 | +10 | 0 | 0 | +10 |
| 08-10 | -40 | 0 | 0 | -40 |
| 08-07 | +19 | 0 | 0 | +19 |
| 08-06 | +5 | 0 | -1 | +4 |
| 08-05 | +2 | 0 | 0 | +2 |
| 08-04 | +32 | 0 | 0 | +32 |
| 08-03 | +5 | 0 | -2 | +3 |
| 07-31 | -18 | 0 | +1 | -17 |
| 07-30 | +24 | 0 | -1 | +23 |
| 07-29 | +211 | 0 | +1 | +212 |
| 07-28 | +100 | 0 | 0 | +100 |
| 07-27 | +18 | 0 | +1 | +19 |
| 07-24 | -50 | 0 | -1 | -51 |
| 07-23 | -4 | 0 | 0 | -4 |
| 07-22 | +22 | 0 | -1 | +21 |
| 07-21 | +67 | 0 | 0 | +67 |
| 07-20 | +80 | 0 | +1 | +80 |
| 07-17 | 0 | 0 | 0 | 0 |
| 07-16 | +63 | 0 | +1 | +64 |
| 07-15 | +35 | 0 | -3 | +32 |
| 07-14 | -1 | 0 | +4 | +3 |
| 07-13 | -18 | 0 | 0 | -18 |
| 07-09 | +1 | 0 | 0 | +1 |
| 07-08 | -18 | 0 | 0 | -18 |
| 07-06 | -13 | 0 | 0 | -13 |
| 07-03 | +91 | 0 | 0 | +91 |
| 07-02 | -11 | 0 | 0 | -11 |
| 07-01 | +23 | 0 | 0 | +23 |
| 06-30 | +38 | 0 | 0 | +38 |
| 06-29 | +28 | 0 | 0 | +28 |
| 06-26 | -24 | 0 | 0 | -24 |
| 06-25 | +58 | 0 | 0 | +58 |
| 06-24 | +57 | 0 | 0 | +57 |
| 06-22 | +45 | 0 | 0 | +45 |
| 06-18 | +4 | 0 | -1 | +3 |
| 06-17 | -37 | 0 | +2 | -35 |
| 06-16 | +81 | 0 | -1 | +80 |
| 06-15 | +47 | 0 | +2 | +49 |
| 06-12 | +30 | 0 | 0 | +30 |
| 06-10 | +13 | 0 | -1 | +12 |
| 06-09 | +9 | 0 | +1 | +10 |
| 06-08 | +23 | 0 | -2 | +21 |
| 06-04 | +6 | 0 | 0 | +6 |
| 06-03 | +82 | 0 | 0 | +82 |
| 06-02 | 0 | 0 | -3 | -3 |
| 06-01 | +40 | 0 | +1 | +41 |
| 05-29 | +15 | 0 | 0 | +15 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/08 | 80 萬 | +30.8% | +153.3% |
| 2026/07 | 61 萬 | +22.3% | +24.5% |
| 2026/06 | 50 萬 | -7.2% | -45.7% |
| 2026/05 | 54 萬 | -33.1% | -24.1% |
| 2026/04 | 81 萬 | +10.8% | +89.9% |
| 2026/03 | 73 萬 | +170.4% | +50.2% |
| 2026/02 | 27 萬 | -30.9% | -8.5% |
| 2026/01 | 39 萬 | -65.1% | -9.5% |
| 2025/12 | 112 萬 | +102.0% | +86.8% |
| 2025/11 | 56 萬 | -51.3% | -50.2% |
| 2025/10 | 114 萬 | +47.5% | +29.1% |
| 2025/09 | 77 萬 | - | +69.7% |